These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine containing serogroups A, C, Y, W, and X in healthy adults: a phase 1, single-centre, double-blind, randomised, controlled study. Chen WH; Neuzil KM; Boyce CR; Pasetti MF; Reymann MK; Martellet L; Hosken N; LaForce FM; Dhere RM; Pisal SS; Chaudhari A; Kulkarni PS; Borrow R; Findlow H; Brown V; McDonough ML; Dally L; Alderson MR Lancet Infect Dis; 2018 Oct; 18(10):1088-1096. PubMed ID: 30120069 [TBL] [Abstract][Full Text] [Related]
4. Immunogenicity and safety of a pentavalent meningococcal ABCWY vaccine in adolescents and young adults: an observer-blind, active-controlled, randomised trial. Peterson J; Drazan D; Czajka H; Maguire J; Pregaldien JL; Seppa I; Maansson R; O'Neill R; Balmer P; Jodar L; Jansen KU; Anderson AS; Perez JL; Beeslaar J Lancet Infect Dis; 2023 Dec; 23(12):1370-1382. PubMed ID: 37579773 [TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and Safety of Investigational MenABCWY Vaccine and of 4CMenB and MenACWY Vaccines Administered Concomitantly or Alone: a Phase 2 Randomized Study of Adolescents and Young Adults. Beran J; Dražan D; Enweonye I; Bhusal C; Toneatto D mSphere; 2021 Dec; 6(6):e0055321. PubMed ID: 34787449 [TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of a booster dose of meningococcal (groups A, C, W, and Y) polysaccharide diphtheria toxoid conjugate vaccine. Robertson CA; Greenberg DP; Hedrick J; Pichichero M; Decker MD; Saunders M Vaccine; 2016 Oct; 34(44):5273-5278. PubMed ID: 27642132 [TBL] [Abstract][Full Text] [Related]
7. A comparative evaluation of two investigational meningococcal ABCWY vaccine formulations: Results of a phase 2 randomized, controlled trial. Block SL; Szenborn L; Daly W; Jackowska T; D'Agostino D; Han L; Dull PM; Smolenov I Vaccine; 2015 May; 33(21):2500-10. PubMed ID: 25795256 [TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and safety of the 4CMenB and MenACWY-CRM meningococcal vaccines administered concomitantly in infants: A phase 3b, randomized controlled trial. Macias Parra M; Gentile A; Vazquez Narvaez JA; Capdevila A; Minguez A; Carrascal M; Willemsen A; Bhusal C; Toneatto D Vaccine; 2018 Nov; 36(50):7609-7617. PubMed ID: 30414782 [TBL] [Abstract][Full Text] [Related]
9. Quadrivalent meningococcal vaccination of adults: phase III comparison of an investigational conjugate vaccine, MenACWY-CRM, with the licensed vaccine, Menactra. Reisinger KS; Baxter R; Block SL; Shah J; Bedell L; Dull PM Clin Vaccine Immunol; 2009 Dec; 16(12):1810-5. PubMed ID: 19812260 [TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and safety of a quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) administered to adults aged 56 Years and older: results of an open-label, randomized, controlled trial. Dbaibo G; El-Ayoubi N; Ghanem S; Hajar F; Bianco V; Miller JM; Mesaros N Drugs Aging; 2013 May; 30(5):309-19. PubMed ID: 23494214 [TBL] [Abstract][Full Text] [Related]
11. Safety of a quadrivalent meningococcal serogroups A, C, W and Y conjugate vaccine (MenACWY-CRM) administered with routine infant vaccinations: results of an open-label, randomized, phase 3b controlled study in healthy infants. Abdelnour A; Silas PE; Lamas MR; Aragón CF; Chiu NC; Chiu CH; Acuña TH; Castrejón Tde L; Izu A; Odrljin T; Smolenov I; Hohenboken M; Dull PM Vaccine; 2014 Feb; 32(8):965-72. PubMed ID: 24397906 [TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and safety of a novel ten-valent pneumococcal conjugate vaccine in healthy infants in The Gambia: a phase 3, randomised, double-blind, non-inferiority trial. Clarke E; Bashorun A; Adigweme I; Badjie Hydara M; Umesi A; Futa A; Ochoge M; Obayemi D; Edem B; Saidy-Jah E; Onwuchekwa C; Dhere R; Sethna V; Kampmann B; Goldblatt D; Taylor D; Andi-Lolo I; Hosken N; Antony K; Innis BL; Alderson MR; Lamola S Lancet Infect Dis; 2021 Jun; 21(6):834-846. PubMed ID: 33516293 [TBL] [Abstract][Full Text] [Related]
13. Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents. Jackson LA; Baxter R; Reisinger K; Karsten A; Shah J; Bedell L; Dull PM; Clin Infect Dis; 2009 Jul; 49(1):e1-10. PubMed ID: 19476428 [TBL] [Abstract][Full Text] [Related]
14. Immunogenicity and safety of the quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in splenectomized or hyposplenic children and adolescents: Results of a phase III, open, non-randomized study. Klein NP; Habanec T; Kosina P; Shah NR; Kolhe D; Miller JM; Hezareh M; Van der Wielen M Vaccine; 2018 Apr; 36(17):2356-2363. PubMed ID: 29576307 [TBL] [Abstract][Full Text] [Related]
15. Comparison of the safety and immunogenicity of an investigational and a licensed quadrivalent meningococcal conjugate vaccine in children 2-10 years of age. Halperin SA; Gupta A; Jeanfreau R; Klein NP; Reisinger K; Walter E; Bedell L; Gill C; Dull PM Vaccine; 2010 Nov; 28(50):7865-72. PubMed ID: 20943209 [TBL] [Abstract][Full Text] [Related]
16. Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial. Snape MD; Perrett KP; Ford KJ; John TM; Pace D; Yu LM; Langley JM; McNeil S; Dull PM; Ceddia F; Anemona A; Halperin SA; Dobson S; Pollard AJ JAMA; 2008 Jan; 299(2):173-84. PubMed ID: 18182599 [TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of meningococcal ACWY CRM197-conjugate vaccine in children, adolescents and adults in Russia. Ilyina N; Kharit S; Namazova-Baranova L; Asatryan A; Benashvili M; Tkhostova E; Bhusal C; Arora AK Hum Vaccin Immunother; 2014; 10(8):2471-81. PubMed ID: 25424958 [TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and safety of the quadrivalent meningococcal vaccine MenACWY-TT co-administered with a combined diphtheria-tetanus-acellular pertussis vaccine versus their separate administration in adolescents and young adults: A phase III, randomized study. Rivera L; Schwarz TF; Kim KH; Kim YK; Behre U; Cha SH; Jo DS; Lee J; Lee JS; Cheuvart B; Jastorff A; Van der Wielen M Vaccine; 2018 Jul; 36(31):4750-4758. PubMed ID: 29960800 [TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine and a quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135, and Y in adults who are at increased risk for occupational exposure to meningococcal isolates. Kimura A; Toneatto D; Kleinschmidt A; Wang H; Dull P Clin Vaccine Immunol; 2011 Mar; 18(3):483-6. PubMed ID: 21177912 [TBL] [Abstract][Full Text] [Related]
20. Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine in Healthy Meningococcal-Naïve Children 2-9 Years of Age: A Phase III, Randomized Study. Baccarini CI; Simon MW; Brandon D; Christensen S; Jordanov E; Dhingra MS Pediatr Infect Dis J; 2020 Oct; 39(10):955-960. PubMed ID: 32852352 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]